Danoprevir is an NS3/4A serine protease inhibitor investigated in combination direct-acting antiviral regimens for hepatitis C virus, requiring pharmacokinetic boosting with ritonavir for clinical efficacy. Simson Pharma's Danoprevir reference standard and impurities support analytical development for this hepatitis C agent.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Danoprevir Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.